Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02767804
Title eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Xcovery Holding Company, LLC
Indications

lung non-small cell carcinoma

Therapies

Crizotinib

Ensartinib

Age Groups: adult
Covered Countries USA | CAN

Additional content available in CKB BOOST